The estimated Net Worth of Timothy R Pearson is at least $246 Тысяча dollars as of 11 November 2022. Mr. Pearson owns over 19,400 units of GlycoMimetics Inc stock worth over $3,944 and over the last 11 years he sold GLYC stock worth over $0. In addition, he makes $242,332 as Independent Chairman of the Board at GlycoMimetics Inc.
Sign up
Mr. Pearson GLYC stock SEC Form 4 insiders trading
Timothy has made over 3 trades of the GlycoMimetics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently he bought 19,400 units of GLYC stock worth $25,026 on 11 November 2022.
The largest trade he's ever made was buying 19,400 units of GlycoMimetics Inc stock on 11 November 2022 worth over $25,026. On average, Timothy trades about 1,482 units every 104 days since 2014. As of 11 November 2022 he still owns at least 24,650 units of GlycoMimetics Inc stock.
You can see the complete history of Mr. Pearson stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Timothy Pearson biography
Timothy R. Pearson serves as Independent Chairman of the Board of the Company. He is no longer as an Independent Director of GlycoMimetics Inc. Effective May 17, 2019. Mr. Pearson most recently held the position of Chief Financial Officer, Executive Vice President and Treasurer at Catalyst Health Solutions, a publicly held pharmacy benefit manager with over $5 billion in revenues. Mr. Pearson led the company’s financial activities, including performance management, investor relations, SEC compliance, capital strategy and planning, until SXC Health Solutions (now Catamaran Corporation) acquired Catalyst in 2012. Mr. Pearson had previously served as Chief Financial Officer and Executive Vice President of MedImmune, the global biologics business for AstraZeneca PLC, where he had functional responsibility for finance, information technology, strategic planning and governance, and was a member of MedImmune’s Executive Team. Mr. Pearson was appointed CFO at Catalyst Health Solutions in July 2011. Before that, he spent 13 years at MedImmune in roles of increasing responsibility. Prior to his promotion to CFO of MedImmune in 2007, he was Vice President of Finance and Treasurer with responsibility for treasury, corporate finance, tax, risk management, Sarbanes-Oxley compliance, internal audit and equity plan administration. During his tenure at MedImmune. Pearson was a founding officer and investment committee member of MedImmune Ventures, MedImmune’s venture capital fund that invests in early-stage biotechnology companies. Mr. Pearson, a Certified Public Accountant, holds dual Bachelor of Science degrees in Business Administration from the University of Delaware and Accounting from the University of Maryland University College, as well as a Master of Science degree in Finance from Loyola University.
What is the salary of Timothy Pearson?
As the Independent Chairman of the Board of GlycoMimetics Inc, the total compensation of Timothy Pearson at GlycoMimetics Inc is $242,332. There are 6 executives at GlycoMimetics Inc getting paid more, with Rachel King having the highest compensation of $2,689,070.
How old is Timothy Pearson?
Timothy Pearson is 52, he's been the Independent Chairman of the Board of GlycoMimetics Inc since 2019. There are 9 older and 6 younger executives at GlycoMimetics Inc. The oldest executive at GlycoMimetics Inc is Dr. John L. Magnani, 68, who is the Sr. VP of Research & Chief Scientific Officer.
What's Timothy Pearson's mailing address?
Timothy's mailing address filed with the SEC is C/O GLYCOMIMETICS, INC., 9708 MEDICAL CENTER DRIVE, ROCKVILLE, MD, 20850.
Insiders trading at GlycoMimetics Inc
Over the last 11 years, insiders at GlycoMimetics Inc have traded over $15,299,593 worth of GlycoMimetics Inc stock and bought 10,868,557 units worth $48,421,008 . The most active insiders traders include Scott D Sandell, Peter J Barris и M James Barrett. On average, GlycoMimetics Inc executives and independent directors trade stock every 51 days with the average trade being worth of $38,210. The most recent stock trade was executed by Public Equities, L.P.Invus ... on 7 August 2024, trading 322,361 units of GLYC stock currently worth $61,249.
What does GlycoMimetics Inc do?
at glycomimetics, we are committed to helping to make a difference in the lives of people living with sickle cell, cancer, and other serious diseases. our mission is to continue to advance our research and clinical candidates, providing hope for patients as we strive for tomorrow’s breakthrough treatments. glycomimetics is a clinical-stage biotechnology company. we use novel and proprietary glycobiology technology to develop treatments for diseases, particularly where there is high unmet need. since the company’s inception in 2003, we have developed a robust, diversified product pipeline. we are a public company traded on the nasdaq under the symbol glyc.
What does GlycoMimetics Inc's logo look like?
Complete history of Mr. Pearson stock trades at GlycoMimetics Inc
GlycoMimetics Inc executives and stock owners
GlycoMimetics Inc executives and other stock owners filed with the SEC include:
-
Rachel King,
President, Chief Executive Officer, Co-Founder, Director -
Brian Hahn,
Chief Financial Officer -
Helen Thackray,
Senior Vice President - Clinical Development, Chief Medical Officer -
John Magnani,
Co-Founder, Senior Vice President, Chief Scientific Officer -
Rachel K. King,
Pres, CEO & Director -
Brian M. Hahn,
Sr. VP & CFO -
Timothy Pearson,
Independent Chairman of the Board -
Daniel Junius,
Independent Director -
Mark Goldberg,
Independent Director -
Scott Jackson,
Independent Director -
Patricia Andrews,
Independent Director -
Scott Koenig,
Independent Director -
Armand Girard,
Senior Vice President, Chief Business Officer -
Bruce Johnson,
Sr. VP & Chief Commercial Officer -
Armand Girard,
Chief Bus. Officer and Sr. VP of Strategy & Corp. Devel. -
Dr. John L. Magnani,
Sr. VP of Research & Chief Scientific Officer -
Harout Semerjian,
CEO, Pres & Director -
Dr. Eric J. Feldman M.D.,
Sr. VP & Chief Medical Officer -
Christian Dinneen-Long,
VP, Corp. Counsel & Corp. Sec. -
Henry Flanner,
VP of Technical Operations -
Stephanie R. Irish,
VP of Accounting -
Partners L P/Ilbiotechnolog...,
-
Scott D Sandell,
10% owner -
Franklin H Jr Top,
Director -
Peter J Barris,
10% owner -
Michael A Henos,
Director -
M James Barrett,
Director -
Enterprise Associates 10 L ...,
-
John J. Baldwin,
Director -
Chinmaya Rath,
SVP and Chief Business Officer -
William M. Gust,
Director -
Enterprise Associates 13 Lp...,
-
Partners L P/Ilbiotechnolog...,
-
Harout Semerjian,
Chief Executive Officer -
Public Equities, L.P.Artal ...,
-
Public Equities, L.P.Invus ...,
-
Bruce S Johnson,
SVP & Chief Commercial Officer -
Edwin Rock,
Chief Medical Officer